Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography

Biomedical Chromatography

Volumn 17, Issue 5, 2003, Pages 335-344

  Johnson, Catharine ^a   Royal, Mabel ^a   Moreadith, Randall ^b   Bedu Addo, Frank ^c   Advant, Siddharth ^a   Wan, Min ^a   Conn, Greg ^a  

^a Diosynth RTP Inc   (United States)

^b ThromboGenics NV   (Belgium)

^c Cardinal Health   (United States)

Author keywords

PEGylation; Reverse phase; Staphylokinase; SY161; Validation

Indexed keywords

AMINO ACIDS; CHROMATOGRAPHIC ANALYSIS; ESCHERICHIA COLI; PROTEINS;

E. COLI; MANUFACTURING PROCESS; PEGYLATED; PEGYLATION; PROCESS STABILITY; PROCESS YIELD; REVERSE PHASIS; REVERSE-PHASE CHROMATOGRAPHY; STAPHYLOKINASE; VALIDATION;

SULFUR COMPOUNDS;

ANTIBODY CONJUGATE; CYSTEINE; DISULFIDE; ENZYME VARIANT; FIBRINOLYTIC AGENT; MACROGOL; MONOCLONAL ANTIBODY; MONOMER; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR; STAPHYLOKINASE; STREPTOKINASE; THIOL DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CROSS LINKING; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; ESCHERICHIA COLI; EXTRACTION; FERMENTATION; HOST CELL; MONITORING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; QUANTUM YIELD; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0042564651     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.249     Document Type: Article

References (39)

1. Alberts MJ. tPA in acute ischemic stroke: United States experience and issues for the future. Neurology 1999; 51: S53-S55.
2. Arvidson S, Eriksson R, Holme T, Mollby R, Wadstrom T and Vesterberg O. Production, purification and partial characterization of staphylokinase. Contributions for Microbiology and Immunology 1973; 1: 406-412.
3. Bedu-Addo F, Moreadith R and Advant S. Preformulation development of staphylokinase SY161 using statistical design methods. AAPS Pharmaceutical Science 2002, 4(4) article 19.
4. Buick AR, Doig MV, Jeal SC, Land GS and MacDowall RD. Method validation in the analytical laboratory. Journal of Pharmaceutical and Biomedical Analysis 1990; 8: 629-637.
5. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature and Medicine 1998; 4: 279-284.
6. Collen D, Bernaerts R, Declerck P, De Cock F, Demarsin E, Jenne S, Laroche Y, Lijnen HR, Silence K and Verstreken M. Recombinant staphylokinase variants with altered inmumoreactivity. I: construction and characterization. Circulation 1996a; 94: 197-206.
7. Collen D, Moreau H, Stockx L and Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. II: thrombolytic properties and antibody induction. Circulation 1996b; 94: 207-216.
8. Collen D, De Cock F, Demarsin E, Jenne S, Lasters I, Laroche Y and Warmerdam P. Jespers L. Recombinant staphylokinase variants with altered immunoreactivity. III: species variability of antibody binding patterns. Circulation 1997a; 95: 455-462.
9. Collen D, Stockx L, Lacroix H and Suy R. Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. IV: identification of variants with reduced antibody induction but intact potency. Circulation 1997b; 95: 463-472.
10. Collen D, Sinnaeve P, Demarsin E, Moreau H, De Maeyer M, Jespers L, Laroche Y and Van De WF. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation 2000; 102: 1766-1772.
11. Crawhall JC and Kalant D. Measurement of biological disulfides by postcolumn sulfitolysis following separation by HPLC. Analytical Biochemistry 1988; 172: 479-483.
12. Damaschun G, Damaschun H, Gast K, Misselwitz R, Zirwer D, Gurs K, Hartmann M, Schlott B, Triebel H and Behnke D. Physical and conformational properties of staphylokinase in solution. Biochimica Biophysica Acta 1993; 1161: 244-248.
13. Dornberger U, Fandrei D, Backmann J, Hubner W, Rahmelow K, Guhrs K, Hartmann M, Schlott B and Fritzsche H. A correlation between thermal stability and structural features of staphylokinase and selected mutants: a Fourier-transform infrared study. Biochimica Biophysica Acta 1996; 1294: 168-176.
14. 2- and COOH-terminal regions of staphylokinase in plasminogen activation. Thromb. Haemost. 1996; 76: 755-760.
15. Goldhaber SZ. A contemporary approach to thrombolytic therapy for pulmonary embolism. Vascular Medicine 2000; 5: 115-123.
16. Jespers L, Vanwetswinkel S, Lijnen HR, Van Herzeele N, Van Hoef B, Demarsin E, Collen D and De Maeyer M. Structural and functional basis of plasminogen activation by staphylokinase. Thromb. Haemost. 1999; 81: 479-485.
17. Kella NK, Kang YJ and Kinsella JE. Effect of oxidative sulfitolysis of disulfide bonds of bovine serum albumin on its structural properties: a physiochemical study. Journal of Protein Chemistry 1988; 7: 535-548.
18. Laroche Y, Heymans S, Capaert S, De Cock F, Demarsin E and Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000; 96: 1425-1432.
19. Lijnen HR and Collen D. Molecular basis of thrombolytic therapy. Journal of Nuclear Cardiology 2000; 7: 373-381.
20. Mach H, Middaugh CR and Lewis RV. Statistical determination of the average values of extinction coefficients of tryptophan and tyrosine in native proteins. Analytical Biochemistry 1992; 200: 74-80.
21. Marder VJ. Thrombolytic therapy: 2001. Blood Review 2001; 15: 143-157.
22. Reddy DS. Newer thrombolytic drugs for acute myocardial infarction. Indian Journal of Experimental Biology 1998; 36: 1-15.
23. Ross AM. New plasminogen activators: a clinical review. Clinical Cardiology 1999; 22: 165-171.
24. Rajamohan G and Dikshit KL. Role of the N-terminal region of staphylokinase (SAK): evidence for the participation of the N-terminal region of SAK in the enzyme-substrate complex formation. FEBS Letters 2000; 474: 151-158.
25. Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeid E, Pohl HD, Vanderschueren S, Van De WF, Michoel A, Collen D and Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology (NY) 1994; 12: 185-189.
26. Schlott B, Guhrs KH, Hartmann M, Rocker A and Collen D. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation. Journal of Biological Chemistry 1997; 272: 6067-6072.
27. Schlott B, Guhrs KH, Hartmann M, Rocker A and Collen D. NH2-terminal structural motifs in staphylokinase required for plasminogen activation. Journal of Biological Chemistry 1998; 273: 22346-22350.
28. Thomson A. New thrombolytic drugs. Australian and New Zealand Journal of Medicine 1999; 29: 433-435.
29. Toombs CF. New directions in thrombolytic therapy. Current Opinion in Pharmacology 2001; 1: 164-168.
30. Trieu T, Behnke D, Gerlach D and Tang J. Activation of human plasminogen by recombinant staphylokinase. Methods in Enzymology 1993; 223: 156-167.
31. United States Pharmacopeia XXIII: Validation of Compendial Methods. USP Convention Inc. 1990; 1710.
32. Vahanian A. Thrombolytic therapy in Europe: current status. European Heart Journal 1996; 17 (Suppl E):21-27.
33. van Rensburg NJ and Swanepoel OA. Reactions of unsymmetrical disulfides. I. Sulfitolysis of sulfur derivatives of cysteamine and cysteine. Archives of Biochemistry and Biophysics 1967a, 118: 531-535.
34. van Rensburg NJ and Swanepoel OA. Reactions of unsymmetrical disulfides. II. Sulfitolysis of disulfide bonds linking proteins to small molecules. Archives of Biochemistry and Biophysics 1967b, 121: 729-731.
35. Vanwetswinkel S, Plaisance S, Zhi-Yong Z, Vanlinthout I, Brepoels K, Lasters I, Collen D and Jespers L. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood 2000, 95: 936-942.
36. van Zyl WB, Pretorius GH, Hartmann M and Kotze HF. Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. Thrombosis Research 1997; 88: 419-426.
37. Verstraete M. Third-generation thrombolytic drugs. American Journal of Medicine 2000; 109: 52-58.
38. Vorchheimer DA. Current state of thrombolytic therapy. Current Cardiology Report 1999; 1: 212-220.
39. Ye R, Kim JH, Kim BG, Szarka S, Sihota E and Wong SL. High-level secretory production of intact, biologically active staphylokinase from Bacillus subtilis. Biotechnology and Bioengineering 1999; 62: 87-96.